Delhi air pollution health risks extend beyond respiratory illness, with prolonged PM2.5 exposure linked to cardiovascular and kidney complications.
Sun Pharma's USD 11.75 billion Organon acquisition involves a USD 4 billion syndicated loan to refinance bridge financing, alongside other funding options to manage acquisition debt and maintain financial flexibility.
Indian homes have always been about art, spirituality, and celebration. You've got your entrance decorated with flowers and diyas, and you've got your prayer room with the idols and all that sort of thing.
Mankind Pharma's ensartinib deal brings Betta Pharmaceuticals' targeted lung cancer treatment closer to the Indian oncology market.
India's first Zika vaccine has moved a step closer to human testing, marking an important development in the country's efforts to strengthen protection against emerging mosquito-borne infections.
Summit Therapeutics' ivonescimab has encountered a regulatory challenge after the US Food and Drug Administration (FDA) declined to approve the investigational lung cancer treatment.
Zydus' UK facility receives four USFDA observations, bringing its LiqMeds acquisition and overseas manufacturing compliance into focus.
Johnson & Johnson’s reported interest in acquiring Ollin Biosciences could strengthen its ophthalmology pipeline and expand its presence in retinal disease treatment.
Public hospitals are gaining attention as Nadda reviews Najafgarh's expansion and rural healthcare infrastructure.
Cancer drug price reductions could ease treatment expenses, while the government's proposed Rs 7,000 crore bulk drug Production Linked Incentive (PLI) scheme aims to strengthen domestic manufacturing.